Lv1
24 积分 2023-03-06 加入
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929
8天前
已完结
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
30天前
已完结
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
2个月前
已完结
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
2个月前
已完结
Atypical Central Retinal Vein Occlusion in an Older Man With Multiple Myeloma: A Case Report
3个月前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
3个月前
已完结
Biomarkers for Antibody–Drug Conjugates in Solid Tumors
3个月前
已完结
Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action
3个月前
已完结
Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates: A review of recent advances and future perspectives
3个月前
已完结
Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms
3个月前
已关闭
皖公网安备34019202002308
